Breast cancer is the most common cancer in women
It is estimated that more than 250,000 new cases will be diagnosed in the US in 2018. 20% of breast cancers lack receptors for three common hormones (oestrogen, progesterone and HER2) and are thus called triple-negative breast cancers (TNBC).
Treatment options for TNBC are limited to intense chemotherapy, but disease recurrence is frequent and aggressive. Consequently, novel treatment strategies for TNBC are urgently needed.
Selective AXL inhibition shows promise for the treatment of TNBC
Pre-clinical and translational evidence suggest that AXL inhibition may be synergistic with immune checkpoint blockade.
- High AXL expression is a negative prognostic factor in TNBC
- Bemcentinib is a selective AXL inhibitor in phase II clinical testing taken orally once a day
- Adding bemcentinib to KEYTRUDA in animal models of TNBC demonstrated increased efficacy
- The BGBC007 clinical trial evaluates bemcentinib in combination with KEYTRUDA (pembrolizumab)